NASDAQ:VTGN - Vistagen Therapeutics Stock Price, Forecast & News

Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN."

Vistagen Therapeutics Inc (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, February, 13th. The company reported ($0.15) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.08. View Vistagen Therapeutics' Earnings History.

Vistagen Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, June 23rd 2020. View Earnings Estimates for Vistagen Therapeutics.

3 analysts have issued 12-month price objectives for Vistagen Therapeutics' stock. Their forecasts range from $0.70 to $4.00. On average, they anticipate Vistagen Therapeutics' stock price to reach $2.35 in the next year. This suggests a possible upside of 360.8% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Vistagen Therapeutics.

Media headlines about VTGN stock have trended negative on Friday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vistagen Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Vistagen Therapeutics.

Vistagen Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,640,000 shares, a decrease of 8.3% from the January 15th total of 2,880,000 shares. Based on an average trading volume of 817,900 shares, the days-to-cover ratio is presently 3.2 days. Currently, 7.0% of the shares of the company are sold short. View Vistagen Therapeutics' Current Options Chain.

Some companies that are related to Vistagen Therapeutics include Xeris Pharmaceuticals (XERS), Zynerba Pharmaceuticals (ZYNE), Sunesis Pharmaceuticals (SNSS), Otonomy (OTIC), Proteostasis Therapeutics (PTI), TFF Pharmaceuticals (TFFP), Aquestive Therapeutics (AQST), Savara (SVRA), Enlivex Therapeutics (ENLV), VERONA PHARMA P/S (VRNA), Sesen Bio (SESN), Checkpoint Therapeutics (CKPT), Immunic (IMUX), Oncolytics Biotech (ONCY) and Neos Therapeutics (NEOS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Matinas BioPharma (MTNB), vTv Therapeutics (VTVT), Lithium Americas (LAC), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP) and Yamana Gold (AUY).

Vistagen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.52%) and Blair William & Co. IL (0.12%). Company insiders that own Vistagen Therapeutics stock include H Ralph Snodgrass and Jon S Saxe. View Institutional Ownership Trends for Vistagen Therapeutics.

VTGN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Vistagen Therapeutics.

VTGN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. Company insiders that have bought Vistagen Therapeutics stock in the last two years include H Ralph Snodgrass and Jon S Saxe. View Insider Buying and Selling for Vistagen Therapeutics.

Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VTGN stock can currently be purchased for approximately $0.51.

Vistagen Therapeutics has a market capitalization of $24.46 million and generates $1.25 million in revenue each year. The company earns $-24,590,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe.View Additional Information About Vistagen Therapeutics.

The official website for Vistagen Therapeutics is http://www.vistagen.com/.

Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected]